LBA
TCRX icon

Letko, Brosseau & Associates’s TScan Therapeutics TCRX Stock Holding History

Letko, Brosseau & Associates’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.8K Hold
95,875
– – ﹤0.01% 96
2025
Q4 		$95.9K Hold
95,875
– – ﹤0.01% 97
2025
Q3 		$174K Hold
95,875
– – ﹤0.01% 92
2025
Q2 		$139K Buy
95,875
+18,775
+24% +$27.1K ﹤0.01% 88
2025
Q1 		$106K Buy
77,100
+40,900
+113% +$88.5K ﹤0.01% 84
2024
Q4 		$110K Buy
36,200
+15,500
+75% +$70.3K ﹤0.01% 96
2024
Q3 		$103K Hold
20,700
– – ﹤0.01% 98
2024
Q2 		$121K Hold
20,700
– – ﹤0.01% 100
2024
Q1 		$164K Hold
20,700
– – ﹤0.01% 97
2023
Q4 		$121K Sell
20,700
-11,700
-36% -$53.6K ﹤0.01% 91
2023
Q3 		$82.9K Buy
+32,400
New +$75.6K ﹤0.01% 94

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Letko, Brosseau & Associates's TCRX Position: Q1 2026 in Review

Letko, Brosseau & Associates held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 95,875 shares worth $96.8K. The position accounts for ﹤0.01% of the portfolio, ranked #96.

Letko, Brosseau & Associates first reported a position in TCRX in Q3 2023 and has held it in 11 quarters since. The position peaked at $174K in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Letko, Brosseau & Associates held 95,875 shares of TScan Therapeutics worth $96.8K as of Q1 2026.
  • Letko, Brosseau & Associates left its TScan Therapeutics share count unchanged in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #96 holding.
  • Letko, Brosseau & Associates first reported a position in TScan Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Letko, Brosseau & Associates's TScan Therapeutics position peaked at $174K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.